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Objectives: A consensus has been reached in The Netherlands that all future medical costs should be included in economic
evaluations. Furthermore, internationally, there is the recognition that in countries that adopt a societal perspective estimates
of future nonmedical consumption are relevant for decision makers as much as production gains are. The aims of this paper
are twofold: (1) to update the tool Practical Application to Include Future Disease Costs (PAID 1.1), based on 2013 data, for the
estimation of future unrelated medical costs and introduce future nonmedical consumption costs, further standardizing and
facilitating the inclusion of future costs; and (2) to demonstrate how to use the tool in practice, showing the impact of
including future unrelated medical costs and future nonmedical consumption in a case-study where a life is hypothetically
saved at different ages and 2 additional cases where published studies are updated by including future costs.
Methods: Using the latest published cost of illness data from the year 2017, we model future unrelated medical costs as a
function of age, sex, and time to death, which varies per disease. The Household Survey from Centraal Bureau Statistiek is
used to estimate future nonmedical consumption by age.
Results: The updated incremental cost-effectiveness ratios (ICERs) from the case studies show that including future costs can
have a substantial effect on the ICER, possibly affecting choices made by decision makers.
Conclusion: This article improves upon previous work and provides the first tool for the inclusion of future nonmedical
consumption in The Netherlands.
Keywords: economic evaluation, future costs, nonmedical consumption, unrelated medical costs.
VALUE HEALTH. 2020; -(-):-–-Introduction
Although cost-utility analysis (CUA) is increasingly used to
assess whether new interventions in healthcare yield sufficient
value for money,1 there are still several methodological issues that
require attention. One such issue is the extent to which future
costs should be included in CUAs,2,3 where future costs are costs
that arise from extending individuals’ lives and include all costs in
the life-years gained (LYG) from an intervention. They are typically
divided into medical (relevant for both societal and healthcare
perspectives) and nonmedical costs (only relevant for the societal
perspective). Nonmedical costs here refer to consumption (eg,
costs for housing and food) minus production (benefits from
additional work in LYG). For medical costs, a distinction is made
between related (eg, costs for check-ups by a cardiologist after a
heart attack) and unrelated costs (eg, costs for treating pneumonia
after said heart attack). Future related medical costs are typically
included in CUAs. Including future unrelated medical costs, how-
ever, has been frequently debated. Early in the debate, the extentuthors contributed equally to this work.
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cess article under the CC BY license (http://creativecommons.org/licenses/bto which future costs should be included was discussed using
theoretical models aiming to optimize societal welfare. This led to
multiple views on the topic,4,5 the most compelling being that all
future costs and benefits should be considered.5 Later, the dis-
cussion was extended with the more practical view that because
future unrelated medical consumption benefits are generally
included, the costs thereof should be included to be consistent.6
This argument was also used to state that future nonmedical costs
should not be included, arguing that the benefits thereof are not
systematically included in the Quality Adjusted Life-Year (QALY).7
There are different views, however, on the extent to which the
benefits from nonmedical consumption and production are actu-
ally included,8–10 and there is so far no compelling (empirical)
evidence regarding this.3 The inclusion of future unrelated medi-
cal costs in CUA is now required in The Netherlands11 and rec-
ommended in the United States.12 Although production in LYG is
often considered part of productivity costs in CUA using a societal
perspective, the inclusion of future nonmedical consumption costs
is only recommended in the United States.12Policy & Management, Erasmus University, P.O. Box 1738, 3000 DR Rotterdam,
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
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The Netherlands, the Practical Application to Include Future Dis-
ease Costs (PAID 1.0) was introduced in 201113 and updated in
2016 (PAID 1.1). This tool provides age and sex-specific average
medical spending estimates, which can be specified to exclude the
costs of specific providers and diseases. Estimates are based on a
conceptual model that combines various streams of the literature.
Costs by age are corrected for “time-to-death” by estimating costs
separately for survivors and decedents. Time to death refers to the
finding that healthcare costs are often higher in the last period of
life.14 Since older people are more likely to die, not correcting for
this leads to an overestimation of the impact of age on medical
expenditures14 and ignores the fact that saving a life at a given age
leads to the postponement of this high-cost last period of life.15
Future related medical costs of specific diseases already included
in the analysis can be excluded to prevent double-counting.
This article provides an extensive update of PAID to PAID 3.0.
First, it uses most recent available cost of illness (COI) data (2017).
Second, and the largest difference from PAID 1.1, future costs of
nonmedical consumption are included. We provide guidance,
supported by 3 case studies, on how to use PAID 3. PAID 3.0 can be
used free of charge via https://imta.shinyapps.io/PAID3/ and con-
sists of a webapp made in Shiny in R.Methods
As stated by Meltzer,5 if the aim of economic evaluations is to
maximize social welfare given available resources, all costs
following from an intervention should be considered. This implies
that both medical costs, related and unrelated, and nonmedical
costs should be included. The incremental cost-effectiveness ratio
(ICER), including all costs can be written as follows:
ICER¼ D ½LY 3 ðRMC1 PCÞ
D QALY
1
DLY 3 UMC
D QALY
1
DLY 3 NMC
D QALY
; (1)
where
 LY = life years;
 RMC = related medical costs;
 PC = productivity costs;
 UMC = unrelated medical costs;
 NMC = costs of nonmedical consumption.
Splitting the ICER equation into 3 ratios distinguishes the el-
ements that are currently included in economic evaluation,
related medical costs, and productivity costs, from the additional
costs that are not usually considered: future unrelated medical
costs and future costs of nonmedical consumption. Equation (1)
also illustrates that differences in unrelated medical costs and
future costs of nonmedical consumption are purely the result of
differences in survival. In our estimation of the ICER, in which
future costs are included, we use per capita medical and
nonmedical consumption cost patterns by age as a starting point.
Lifetime costs of unrelated medical and nonmedical con-
sumption LY 3 ½UMC1NMC for an individual aged a dying at age
n, can be written as shown in Eq. (2):
LY3½UMC1NMC ¼
Xn21
a
X
i
sciðaÞ1
X
i
dciðnÞ 1
Xn
a
nmcðaÞ; (2)
where
 a = age in years; n = age at death;
 dc = decedent costs (healthcare costs in last year of life);
 sc = survivor costs (healthcare costs in other years);
 nmc = average costs of nonmedical consumption;
 i = index of unrelated diseases.
Unrelated Medical Costs
Rather than taking a bottom-up approach and predicting the
risk of all unrelated diseases and connecting these to costs, we
take a top-down approach and use total per capita healthcare
costs by age and sex as a starting point for estimating unrelated
medical costs. Using methods identical to those of van Baal and
colleagues,13 we first break down total healthcare costs by disease,
enabling the exclusion of costs for diseases already included in the
analysis. Although we explain these methods in the ensuing text,
for a more detailed description we refer to the original paper by
van Baal and colleagues.13 Disease-specific per capita healthcare
costs were estimated using data from the Dutch COI from 2017.16
Rather than using the system of health accounts 17 perspective
(used in PAID 1.1), we use the classification from the National
Institute for Public Health and the Environment (RIVM). Although
the system of health accounts is internationally recognized, the
RIVM definition includes more healthcare costs, such as interna-
tional care. Whereas average per capita spending hardly changed
between 2013 and 2017, age and disease patterns have changed.
For example, between 2013 and 2017, costs of psychological dis-
orders increased 14% when using 2017 prices—far more than costs
in other disease categories, such as diseases of the central nervous
system (2% when using 2017 prices).
COI data are specified by sex and 21 age-classes, which we
interpolated using cubic splines to obtain age-year-specific per
capita expenditures, and which are calculated from population
spending totals. The data are further attributed to 100 disease
categories and 11 healthcare provider categories (overview in
Appendix A in Supplemental Materials found online at https://doi.
org/10.1016/j.jval.2020.07.004.) These disease categories include
“Not disease-related” and “Not allocated,” meaning that these are
also included in our definition of unrelated medical costs. Because
healthcare costs are strongly determined by both age and time to
death,18 individual lifetime healthcare costs can be estimated as
shown in the first 2 parts of Eq. (2). To obtain estimates for sur-
vivors and decedents, average per capita expenditures are divided
into 1 part attributable to those dying and 1 part to those sur-
viving at that particular age, assuming average costs are a
weighted average of costs for survivors and decedents (age and
sex indices are left out here for notational purposes):
aci ¼ð12mÞ 3 sci1m 3 dci; (3)
where
 aci = average per capita healthcare expenditure for disease i;
 m = mortality rate.
Disease-specific costs for survivors and decedents can be
estimated using Eq (4), using mortality rates and the sex- and age-
dependent ratios between costs for decedents and survivors (ri):
dci ¼ ri 3 sci; (4)
aci ¼ sci1 ðri21Þ3m 3 sci;
sci ¼
aci
1 1 ðri 2 1Þ 3m
;
-- 3Mortality rates from 2017 were obtained from Statistics
Netherlands.19 We used the same disease-specific ratios for costs
between decedents and survivors for the hospital sector as used in
previous versions of PAID. For ambulatory healthcare, drugs and
appliances, and nursing and residential care, ratios from
1999 based on total expenditures were used.20 To obtain
disease-specific ratios for these providers, we exponentiated
disease-specific hospital ratios by a scaling constant describing the
relation between costs for decedents and survivors between
hospital care and other providers (see Appendix C in Supple-
mental Material found online at https://doi.org/10.1016/j.jval.202
0.07.004). For providers for which no ratios were available, we
assumed that costs for decedents were equal to costs for survivors,
as it is predominantly in hospitals that differences in survivor and
decedent costs are observed.18–21
Nonmedical Consumption
To estimate costs of nonmedical consumption by age, we
used data from the cross-sectional Dutch Household Consump-
tion survey from 2004 adjusted to 2017 price levels using
consumer price indices from Statistics Netherlands. In previous
literature, economies of scale within households have been
found to be important when estimating nonmedical consump-
tion,22,23 implying lower per person consumption costs when
household size is larger. For instance, spending on housing can
be divided among more people when household size is larger;
however, the utility obtained from housing is likely to be the
same whether someone lives on their own or not. This has
important implications for estimating future costs of nonmed-
ical consumption because preventing a death in a single-person
household will result in more future nonmedical consumption
than preventing a death in a multiperson household.24 To es-
timate costs of nonmedical consumption for an average
household by age, we fit 2 generalized additive models using
penalized B-splines on age. The first model estimates annual
consumption per household equivalent. Consumption per
household equivalent is calculated from household consumption
using the Organisation for Economic Co-operation and Devel-
opment modified equivalence scale.25 The Organisation for
Economic Co-operation and Development modified equivalence
scale assigns a weighting factor of 0.5 to each additional adult
household member and 0.3 to each child in a multiperson
household. The second model estimates the probability of a
household having more than 1 adult; we are interested in
making predictions for an average household. Using this
equivalence scale implies that preventing a death in a single-
person household results in twice as much nonmedical con-
sumption as compared with a multiperson household with two
adults. Details on these models and testing of assumptions can
be found elsewhere.23 The models are used to estimate average
annual nonmedical consumption by age of preventing a death
in an average household as in Eq. (5):
nmcðaÞ¼ ½hh equivðaÞ3hðaÞ3w1½hh equivðaÞ3 ð12hðaÞÞ; (5)
where
 h = probabilitity of household having .1 adult;
 hh equiv = annual nonmedical consumption per household-
equivalent;
 w = weight of deceased household member: .5 for an adult and
.3 for a child.Case Studies
We demonstrate the impact of including future costs on the
ICER via 3 case studies. Benefits are discounted at 1.5% per year
and costs at 4% per year, in adherence with Dutch guidelines.11
For the first case study, a life is hypothetically saved at ages 0 to
100, whereas in the second and third case studies, we replicate
survival curves from previous studies. In the first case study, life
tables for estimating life expectancy at all ages are used and
combined with quality-of-life data from Gheorghe and
colleagues.26
For the second case study, we replicated survival curves from a
previously published cost-effectiveness study on oxaliplatin plus
fluoropyrimidines versus fluoropyrimidines only as adjuvant
treatment of stage 3 colon cancer,27 wherein oxaliplatin showed
an incremental QALY gain of 1.02 and 0.68 LYG, incremental costs
of V9961, and a corresponding ICER of V9766. The sample con-
sisted of patients previously diagnosed with stage 3 colon cancer
who were randomized to either treatment or control groups. The
median age of patients was 60 years. This study is then updated by
including estimates of future medical costs, after excluding costs
related to colon cancer, and including future nonmedical
consumption.
For the third case study, we used the results from a clinical trial
assessing survival of pembrolizumab monotherapy compared to
platinum-based chemotherapy in a group of previously untreated
patients with locally advanced or metastatic non–small-cell lung
cancer.28 The paper from which the survival curves are extracted
does not perform a CEA, and therefore there are no “baseline” ICER
or QALY gains. In this clinical trial, the median age at baseline was
64 years of age, and 71% of patients were male. This case study
demonstrates how to use PAID when survival is short. We
recommend using estimates of living 1 year longer when studies
have a relatively short time-horizon (,5 years as rule of thumb),
especially when survival between the new treatment and
comparator are highly different in the first study-year. In that case,
using decedent costs would create large differences in costs at
baseline between the new treatment and the comparator for un-
related diseases. This is implausible because it implies a different
past trajectory of costs for the same person before getting the
treatment and conflicts with the definition of unrelated medical
costs. Costs for living 1 year longer at a particular age, cðaÞ, can be
calculated as follows:
cða; gÞ¼ scða; gÞ1dcða11; gÞ 2 dcða; gÞ; (6)
where
 c = costs of living one year longer;
 a = age in years;
 g = gender.
Furthermore, although the approach discussed earlier assumes
independence between the healthcare intervention and cost of
nonmedical and unrelated medical consumption, we provide a
framework allowing for a correlation between the intervention
and unrelated medical costs—applied in the third case study. We
show the impact of adjusting PAID estimates of unrelated medical
costs for this correlation, which is relevant when the studied
population is expected to have a different healthcare use for un-
related diseases than the average population. Estimates can be
adjusted using the framework as displayed in Eq. (7), where per
capita costs are shown as the product of disease prevalence and
Figure 1. (A and B) Average per capita medical costs and nonmedical consumption by age. (C and D) Medical costs, split into survivor
and decedent costs by age.
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4 VALUE IN HEALTH - 2020per patient costs:
scðaÞi ¼pðijaÞ 3 scðajiÞi; (7)
dcðaÞi ¼mðajiÞ3dcðajiÞi;
where
 p(i|a) = probability of disease i conditional on age a;
 m(a|i) = mortality rate at age a conditional on having disease i;
 sc(a|i) = survivor costs at age a conditional on having disease i;
 dc(a|i) = decedent costs at age a conditional on having disease i.
Given the relationships displayed in Eq. (7), we adjusted un-
related costs to reflect higher prevalence and mortality for stroke
among patients with lung cancer.29 We adjusted the unrelated
costs for stroke by extracting the costs for stroke separately,
multiplying stroke costs with the relative risk of stroke—1.47—as
estimated by Chen and colleagues29 and adding these back to the
sum of unrelated medical costs, as shown in the equations below.
scðaÞ¼
X
i s j
sciðaÞ1 scjðaÞ 3 l; (8)dcðaÞ¼
X
i s j
dciðaÞ1 dcjðaÞ 3 l;
where
 j = unrelated disease with higher costs (e.g. stroke);
 l = multiplier.
To demonstrate how to use PAID with survival data on an in-
dividual level, we fitted 2 parametric survival models, assuming a
Weibull distribution to overall survival results presented in the
Kaplan–Meier plot28 from which we randomly drew individual
survival times.Results
Unrelated Medical Costs and Nonmedical Costs
Panels A and B in Figure 1 show how average healthcare ex-
penditures rise sharply after age 75, whereas per capita
nonmedical consumption shows a less strong age pattern but
decreases at old age and peaks at middle age (identical numbers
Table 1. The impact of including future costs on the ICER for case studies 2 and 3.
Case study 2 (V per QALY*) Case study 3 (V per life-year)
Unadjusted Adjusted for stroke
Original ICER 9580 N/A N/A
Impact including unrelated medical costs
on ICER
3761 (13 341) 5546 5619
Impact including nonmedical costs on
ICER
5440 (15 020) 9126 9126
Total impact on ICER 9201 (18 781) 14 672 14745
*Total ICER shown in brackets.
-- 5for males and females because estimates are not sex specific).
These graphs show that up until around age 75, people have
higher nonmedical costs than healthcare consumption, whereas
afterward, healthcare exceeds nonmedical consumption.
Age-specific per capita medical costs for survivors and de-
cedents are presented in graphs C and D, showing comparable
patterns in spending by sex, although women’s expenditures are
higher, especially at older ages. These graphs show that differ-
ences between survivor and decedent costs are highest in the first
year of life and between 50 and 75 years and become smaller at
the highest ages. This can largely be attributed to causes of death
and related periods of illness before dying at different ages. In the
first year of life, death often follows a period with high use of
medical care. The same holds for middle age. At the highest ages,
survivors and decedents typically incur higher healthcare expen-
ditures, narrowing the difference in costs.Figure 2. Case study 1. The hypothetical impact of including future un
on the ICER when death is prevented (for free) at a certain age.
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For the first case study, we estimated the impact of including
future costs on the ICER when death is prevented at a certain age
(see Fig. 2). It shows that the older people get, the more expensive
it is to save them.
The results of the second and third case study are summarized
in Table 1. Figures 3 and 4 show differences in costs and survival
over time for the two case studies. Including future unrelated
medical costs in case study 2 leads to an increase of V3761 in the
ICER; including nonmedical consumption adds another V5440 to
the ICER.
For the third case study, we estimated a mean survival of 25.1
months for the intervention group (pembrolizumab) and 15.3
months for the comparator group (chemotherapy). Figure 4
(bottom) shows difference in survival. As stated above, in thisrelated medical costs and future nonmedical consumption (NMC)
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Figure 3. Case study 2. The added costs for including unrelated consumption and nonmedical consumption (top), and the difference in
survival between intervention and comparator group (bottom).
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6 VALUE IN HEALTH - 2020study no baseline ICERs and QALYs were available. Therefore, only
the impact of inclusion on the ICER can be estimated, and impact
is shown as cost per LYG. We estimated a discounted LYG of 0.77
for the intervention group compared to the comparator. Inclusion
of future unrelated medical costs increased the ICER by V5546, orFigure 4. Case study 3. The additional costs by time for the lung can
adjusted for increased stroke risk (top right). Difference in survival be
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nonmedical consumption further increased the ICER to V9126.
Note here that the impact on the ICER will be different when
QALYs instead of life-years are used. If the LYG will be in less than
perfect health, this will increase the impact on the ICER.cer intervention (top left), and the additional costs by time when
tween intervention and comparator group (bottom).
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-- 7Discussion and Conclusion
In 2011, a practical tool to include future unrelated medical
costs in a standardized manner was introduced.13 In this paper, we
updated the tool with the most recent data on medical costs and
included estimates for future nonmedical consumption. Recent
COI data were combined with mortality data and decedent-
survivor cost ratios to provide disease-specific estimates of med-
ical expenditures per capita in survivors and decedents. Related
costs of an intervention are then excluded from total medical
expenditure. Nonmedical consumption was estimated taking into
account household economies of scale. Using case studies, this
paper further demonstrated how to use the tool in practice.
The first case study refers to the situation of saving a life at a
given age, with no intervention costs. It shows that the impact of
including future costs becomes larger at higher ages, mainly
owing to rising healthcare expenditures with age, whereas in
comparison to future medical costs, the impact of including
nonmedical consumption remains relatively stable over time. The
consumption curve (Fig. 1) follows a U-shape as seen in previous
literature22,36; however, when dividing these costs by QALY
changes, the curve flattens considerably. Another factor affecting
the relative impact of including future costs at younger ages
versus older ages is that the more expensive (older) years are
discounted more highly when lives are saved at younger ages.
Furthermore, the impact of including future nonmedical con-
sumption is larger than including future unrelated medical costs
until approximately the age of 60. This may seem surprising when
looking at Figure 1, which shows that per capita nonmedical
consumption is larger than medical consumption until approxi-
mately the age of 75. When estimating the impact of including
future unrelated medical costs on saving a life at different ages,
however, we consider time to death. As a result, high medical
spending in the last year is postponed, and additional medical
spending is less than suggested by Figure 1.
In the second case study, a published evaluation comparing
interventions for colon cancer is replicated. Including future un-
related medical costs increases the ICER by almost 40%, and when
all future costs are included, the ICER more than doubles. In The
Netherlands, a cost-effectiveness threshold ranging from V20 000
up to V80 000 per QALY gained is applied, where the height de-
pends on the principle of proportional shortfall.30,31 Using the
iMTA Disease Burden Calculator,32 we calculated a proportional
shortfall for this case study of 0.37, which implies that the relevant
threshold in this case study is V20 000.31 Including future costs in
this study could thus make this intervention not cost-effective
because it pushes the ICER near the threshold. It is important to
note that an intervention being not cost-effective is not an un-
desirable outcome, but simply the result of correctly estimating
the change in costs for an intervention.
In the third case study, we demonstrate how to adjust for short
time horizons and show that PAID estimates can easily be applied
to several forms of models. Furthermore, we show how to adjust
estimates when costs for unrelated diseases in the studied pop-
ulation are suspected to differ from the costs for the general
population. This is adjusted for here by using the increased risk of
stroke among patients with lung cancer. In this case, the differ-
ence between future unrelated medical costs, whether adjusted or
unadjusted, is relatively small. If the costs of a disease for which
the risk is increased were large and the additional risk substantial,
the impact of such adjustment would be larger, as shown by
Manns et al in their paper on end-stage renal disease care.33
An important limitation to the study is that there are no more
recently estimated decedent-survivor cost ratios than those usedhere. Although more recent estimates of mean overall spending in
the last year of life compared to other years show comparable
numbers,34 more detailed estimates may show different patterns.
An update of these ratios would be useful for future research. A
further limitation with regard to decedent–survivor cost ratios is
that we did not have estimates for all providers, and disease-
specific estimates for 3 providers were derived by combining
hospital estimates with provider-specific sector estimates. In a
similar vein, the classification of costs among providers was
different for 2017 COI data, and therefore fewer costs could be
adjusted using these ratios. It is also worth noting that data from
the household survey are relatively old; although data are
adjusted to 2017 prices, changes in spending patterns by age may
not be captured. Furthermore, we estimated nonmedical con-
sumption by age and assumed no correlation between nonmedical
consumption and disease. Although there is relatively little liter-
ature covering this topic, there are some findings that suggest
such a correlation. For example, it may be that medical con-
sumption crowds out nonmedical consumption for the severely ill,
although this is unlikely in the Dutch context, given that almost all
healthcare spending is publicly financed.35 The findings that
nonmedical consumption decreases from a certain age,22,36,37
however, may imply that as health decreases (as it does at older
ages) so does nonmedical consumption. Further research in this
area is needed.
Finally, we do not address uncertainty in this paper. Uncer-
tainty could stem from the 2 key elements of our estimates: sur-
vival and costs. The original costs in this case are averages
provided by Statistics Netherlands and are therefore with little
surrounding uncertainty. However, there are still sources of un-
certainty, such as decedent-survivor cost ratios; the larger the
time to death effect (larger ratios), the smaller the impact of future
costs on the ICER.5
In general, including future costs may have a systematic effect
on reimbursement decisions because the “upward” effect on the
ICER changes differently by population and intervention. As the
cost of extending life increases with age, this implies that the age
at which an intervention is given will be of increased importance
for the cost-effectiveness of an intervention. Another parameter
that affects the magnitude of the impact of including future costs,
and thus decisions, is the ratio of life-years gained to QALYs gained
for a particular intervention. It has been shown that the larger this
ratio, the larger the impact of including future costs.5
In this paper, no specific attention is paid to future related
medical costs and future productivity because these are typically
already included in economic evaluations, and extensive guidance
on how to estimate and include these costs is already available in
The Netherlands.38 When looking at the total impact of including
future costs, production gained at working ages would presum-
ably lead to those years being the least costly. This would, how-
ever, also depend on how productivity is measured. In The
Netherlands, these costs are typically quantified using the friction
costs method and thus are limited to the friction period. Using the
human capital approach or including informal and household
production would affect the impact of inclusion at different ages.
The latter methods would imply higher negative costs (more
productivity gains from living longer) and thereby lower ICERs.
Another issue worth mentioning is that, although there is agree-
ment that including future unrelated medical costs would
improve the internal consistency of the ICER, implying that costs
are included when related benefits are included, how much QALYs
capture the benefits from nonmedical consumption (and also
production) is currently unclear.6 Furthermore, it is also unclear to
what extent thresholds to which ICERs are compared include
8 VALUE IN HEALTH - 2020these benefits.3 The impact of including future nonmedical con-
sumption and the comparison with existing thresholds should
thus be interpreted with caution.
To conclude, this article provides an update and extension of
PAID and demonstrates through case studies the application and
impact of including future costs in economic evaluations. Updated
ICERs show that including future costs, even just unrelated med-
ical costs, can have a substantial effect on the ICER, which could
affect decision makers’ choices. For future research, it would be
interesting to see the estimates used in a variety of economic
evaluations.
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